Zobrazeno 1 - 10
of 259
pro vyhledávání: '"Grace K Dy"'
Autor:
Dmitriy Zamarin, Diwakar Davar, Adel Samson, Kevin J Harrington, Siddharth Sheth, Eric Tu, Mitesh J Borad, Grace K Dy, Evanthia Galanis, Fernanda Arnaldez, Sandip P Patel, Nicholas Durham, Benedito A Carneiro, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Kevin Laubscher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant
Externí odkaz:
https://doaj.org/article/9b8ca43a8d514a34aab835d920738e15
Autor:
Edward J Spangenthal, Igor Puzanov, Marc S Ernstoff, Pankit Vachhani, Fumito Ito, Ankita Kapoor, Benjamin Switzer, Poornima Subramanian, Yan V Yatsynovich, David M Jacobs, Maya R Chilbert, Umesh C Sharma, Steven G Feuerstein, Filip Stefanovic, Mark D Hicar, Anne B Curtis, Grace K Dy, Brian J Page, Nikhil Agrawal, Arjun Khunger, Alexander Hattoum, Jerome J Schentag
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. Th
Externí odkaz:
https://doaj.org/article/26e58c0f16aa4f4d82e356fda713f180
Autor:
Nikhil Agrawal, Arjun Khunger, Pankit Vachhani, Teresa A. Colvin, Alexander Hattoum, Edward Spangenthal, Anne B. Curtis, Grace K. Dy, Marc S. Ernstoff, Igor Puzanov
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 1, Pp 260-276 (2019)
The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptom
Externí odkaz:
https://doaj.org/article/050b36a63cac4605ad2f222a88150cca
Autor:
Shabnam Rehman, Grace K. Dy
Publikováno v:
European Medical Journal, Vol 4, Iss 1, Pp 100-111 (2019)
Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life. For the treatment of non-small cell lung cancer, several agents wit
Externí odkaz:
https://doaj.org/article/e7ef6bc306d44eec9f5c055640a53b41
Autor:
Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Daniele Marin, Jason Zhu, Jeff Clarke, Matthew Labriola, Shannon McCall, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Arun Singavi, Ben George, Andrew Craig MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Lynn Dressler, Mark Steciuk, Oliver Binns, Deepa Kasuganti, Neel Shah, Marc Ernstoff, Kunle Odunsi, Razelle Kurzrock, Mark Gardner, Lorenzo Galluzzi, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other
Externí odkaz:
https://doaj.org/article/4f4efc20d258452fa94c335442c051f9
Autor:
Grace K. Dy, Mary K. Nesline, Antonios Papanicolau-Sengos, Paul DePietro, Charles M. LeVea, Amy Early, Hongbin Chen, Anne Grand’Maison, Patrick Boland, Marc S. Ernstoff, Stephen Edge, Stacey Akers, Mateusz Opyrchal, Gurkamal Chatta, Kunle Odunsi, Sarabjot Pabla, Jeffrey M. Conroy, Sean T. Glenn, Hanchun T. DeFedericis, Blake Burgher, Jonathan Andreas, Vincent Giamo, Maochun Qin, Yirong Wang, Kazunori Kanehira, Felicia L. Lenzo, Peter Frederick, Shashikant Lele, Lorenzo Galluzzi, Boris Kuvshinoff, Carl Morrison
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of cancer as standard care. Recent FDA guidance for the classification of g
Externí odkaz:
https://doaj.org/article/5167cae0cf364fa38ba58c2973088fd1
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Autor:
Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoine Italiano, Jürgen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong-Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schuler, Pascale Tomasini, David S. Hong, Piro Lito, Qui Tran, Simon Jones, Abraham Anderson, Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T. Li
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54309264d1f0d6739802d358f609072
https://lirias.kuleuven.be/handle/20.500.12942/719125
https://lirias.kuleuven.be/handle/20.500.12942/719125
Autor:
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:7-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4ae99bafe70d07102f42b5929800257
https://doi.org/10.1007/s00280-022-04443-1
https://doi.org/10.1007/s00280-022-04443-1
Autor:
Chang-Chieh Hsu, Yunchen Yang, Eric Kannisto, Xie Zeng, Guan Yu, Santosh K. Patnaik, Grace K. Dy, Mary E. Reid, Qiaoqiang Gan, Yun Wu
Publikováno v:
ACS Nano
Tumor derived exosomes (TEXs) have emerged as promising biomarkers for cancer liquid biopsy. Conventional methods (such as ELISA and qRT-PCR) and emerging biosensing technologies mainly detect a single type of exosomal biomarker due to the distinct p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0101ff2493ae6cbc02aa87fa769acd85
https://europepmc.org/articles/PMC10266547/
https://europepmc.org/articles/PMC10266547/